

# World Journal of *Gastrointestinal Pharmacology and Therapeutics*

*World J Gastrointest Pharmacol Ther* 2018 February 6; 9(1): 1-15





**MINIREVIEWS**

- 1 Monitoring inflammatory bowel disease during pregnancy: Current literature and future challenges  
*Choden T, Mandaliya R, Charabaty A, Mattar MC*

**ORIGINAL ARTICLE**

**Retrospective Study**

- 8 Declining use of combination infliximab and immunomodulator for inflammatory bowel disease in the community setting  
*Berkowitz JC, Stein-Fishbein J, Khan S, Furie R, Sultan KS*

**CORRECTION**

- 14 Erratum for factors associated with visceral fat accumulation in the general population in Okinawa, Japan  
(*World J Gastrointest Pharmacol Ther* 2016; 7: 261-267)  
*Arakaki S, Maeshiro T, Hokama A, Fujita J*

## Contents

*World Journal of Gastrointestinal Pharmacology and Therapeutics*

Volume 9 Number 1 February 6, 2018

### ABOUT COVER

Editorial Board Member of *World Journal of Gastrointestinal Pharmacology and Therapeutics*, Jeong Won Jang, MD, PhD, Associate Professor, Department of Internal Medicine, The Catholic University of Korea, Seoul 137-701, South Korea

### AIM AND SCOPE

*World Journal of Gastrointestinal Pharmacology and Therapeutics* (*World J Gastrointest Pharmacol Ther*, *WJGPT*, online ISSN 2150-5349, DOI: 10.4292), is a peer-reviewed open access academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

*WJGPT* covers topics concerning: (1) Clinical pharmacological research articles on specific drugs, concerning with pharmacodynamics, pharmacokinetics, toxicology, clinical trial, drug reactions, drug metabolism and adverse reaction monitoring, etc.; (2) Research progress of clinical pharmacology; (3) Introduction and evaluation of new drugs; (4) Experiences and problems in applied therapeutics; (5) Research and introductions of methodology in clinical pharmacology; and (6) Guidelines of clinical trial.

We encourage authors to submit their manuscripts to *WJGPT*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great basic and clinical significance.

### INDEXING/ABSTRACTING

*World Journal of Gastrointestinal Pharmacology and Therapeutics* is now indexed in PubMed, PubMed Central.

### EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xiang Li*  
Responsible Electronic Editor: *Rui-Fang Li*  
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Li-Jun Cai*  
Proofing Editorial Office Director: *Xin-Xia Song*

#### NAME OF JOURNAL

*World Journal of Gastrointestinal Pharmacology and Therapeutics*

#### ISSN

ISSN 2150-5349 (online)

#### LAUNCH DATE

May 6, 2010

#### FREQUENCY

Quarterly

#### EDITOR-IN-CHIEF

**Hugh J Freeman, MD, FRCPC, FACP, Professor,**  
Department of Medicine (Gastroenterology), University of British Columbia, Hospital, 2211 Wesbrook Mall, Vancouver, BC V6T1W5, Canada

#### EDITORIAL BOARD MEMBERS

All editorial board members resources online at <http://www.wjgnet.com/2150-5349/editorialboard.htm>

#### EDITORIAL OFFICE

Xiu-Xia Song, Director  
*World Journal of Gastrointestinal Pharmacology and Therapeutics*  
Baishideng Publishing Group Inc  
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA  
Telephone: +1-925-2238242  
Fax: +1-925-2238243  
E-mail: [editorialoffice@wjgnet.com](mailto:editorialoffice@wjgnet.com)  
Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjgnet.com>

#### PUBLISHER

Baishideng Publishing Group Inc  
7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA  
Telephone: +1-925-2238242  
Fax: +1-925-2238243  
E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjgnet.com>

#### PUBLICATION DATE

February 6, 2018

#### COPYRIGHT

© 2018 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

#### SPECIAL STATEMENT

All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

#### INSTRUCTIONS TO AUTHORS

<http://www.wjgnet.com/bpg/gerinfo/204>

#### ONLINE SUBMISSION

<http://www.f6publishing.com>

## Monitoring inflammatory bowel disease during pregnancy: Current literature and future challenges

Tenzin Choden, Rohan Mandaliya, Aline Charabaty, Mark C Mattar

Tenzin Choden, Department of Internal Medicine, MedStar Georgetown University Hospital, Washington, DC 20007, United States

Rohan Mandaliya, Aline Charabaty, Mark C Mattar, Division of Gastroenterology, MedStar Georgetown University Hospital, Washington, DC 20007, United States

ORCID number: Tenzin Choden (0000-0002-6939-1551); Rohan Mandaliya (0000-0002-0749-9022); Aline Charabaty (0000-0001-9810-3662); Mark C Mattar (0000-0002-9339-1607).

**Author contributions:** Choden T and Mandaliya R wrote the manuscript; Charabaty A and Mattar MC provided input on designing the outline and coordinated the writing of the paper.

**Conflict-of-interest statement:** There is no conflict of interest associated with any of the senior author or other coauthors contributed their efforts in this manuscript.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to:** Mark C Mattar, MD, FACP, Division of Gastroenterology, MedStar Georgetown University Hospital, 3800 Reservoir Rd NW, Washington, DC 20007, United States. [mark.c.mattar@gunet.georgetown.edu](mailto:mark.c.mattar@gunet.georgetown.edu)  
Telephone: +1-202-4441039  
Fax: +1-877-3031462

Received: July 29, 2017

Peer-review started: July 30, 2017

First decision: September 6, 2017

Revised: October 13, 2017

Accepted: October 30, 2017

Article in press: October 30, 2017

Published online: February 6, 2018

### Abstract

Inflammatory bowel disease has a high prevalence in women of childbearing age and can have a significant impact on pregnancy, from conceiving to carrying the pregnancy. Active disease during pregnancy is known to have negative effects on pregnancy outcomes; therefore, careful monitoring during this period is an important but challenging aspect of care and is crucial as it affects important management decisions. Recent data seems to suggest that endoscopy is a relatively safe procedure during all trimesters of pregnancy. Serum biomarkers such as C-reactive protein and fecal calprotectin are helpful non-invasive markers, but have shown conflicting results for correlation with disease activity in some initial studies. Further work is necessary to establish standard of care monitoring during pregnancy.

**Key words:** Inflammatory bowel disease; Crohn's disease; Ulcerative colitis; Pregnancy; Fecal calprotectin

© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** This review article fills in the gap in the paucity of literature specifically focusing on the monitoring of inflammatory bowel disease during pregnancy. New and emerging literature on the use of non-invasive biomarkers such as fecal calprotectin is discussed, but classic monitoring techniques such as endoscopy and radiographic imaging are also evaluated within the scope of pregnancy.

Choden T, Mandaliya R, Charabaty A, Mattar MC. Monitoring inflammatory bowel disease during pregnancy:

Current literature and future challenges. *World J Gastrointest Pharmacol Ther* 2018; 9(1): 1-7 Available from: URL: <http://www.wjgnet.com/2150-5349/full/v9/i1/1.htm> DOI: <http://dx.doi.org/10.4292/wjgpt.v9.i1.1>

## INTRODUCTION

Inflammatory bowel disease (IBD) has a high prevalence in young adults and affects many women of childbearing age. Having IBD has many effects on women who are contemplating having children, ranging from conceiving to carrying the pregnancy, concerns about passing the disease onto children, fetal outcomes, and effects of pregnancy on the disease process itself.

Many women with IBD have poor knowledge about their ability to bear children or the effect that IBD will have on their pregnancy, with a tendency to overestimate the effects of IBD on fertility<sup>[1,2]</sup>. This has led to the phenomenon of voluntary childlessness, which affects up to 18% of women with IBD as compared to 6% in the general population. Women with IBD have misconceptions about a decreased rate of fertility, fear of passing on the condition onto offspring, and concerns over the effects of the disease on pregnancy outcomes<sup>[3]</sup>. In fact, multiple studies have shown that overall rates of fertility between the general population and women with IBD in clinical remission are comparable<sup>[4]</sup>. However, this trend excludes women who had pelvic surgical procedures, and in particular ileal pouch-anal anastomosis (IPAA) procedures for ulcerative colitis (UC), which have a relative risk of infertility of 3.91 as compared to the general population<sup>[5]</sup>.

Most women who have a quiescent disease before pregnancy have normal pregnancy outcomes. However, active disease upon conception or during pregnancy has been shown to increase adverse outcomes such as low birth weight, preterm birth, and fetal loss<sup>[6]</sup>. In a recent retrospective study following 406 pregnant Indian IBD patients, pregnancies after disease onset were associated with higher number of adverse fetal outcomes and cesarean sections compared to before disease onset<sup>[7]</sup>. Similarly, a study from Denmark sought to evaluate birth outcomes with a cohort of women on anti-TNF therapy during pregnancy. Disease activity was associated with adjusted odds ratio of 2.05 for low birth weight and 2.64 for preterm birth, with the ratio for preterm birth increasing to 3.60 for patients with clinical moderate to severe disease activity<sup>[8]</sup>. In addition to disease activity, inadequate gestational weight gain in the IBD population has been shown to have a 2-fold increase in risk of low gestational weight compared with non-IBD patients with inadequate gestational weight gain in a Norwegian cohort study<sup>[9]</sup>. This finding has been reproduced in a prospective American cohort study for Crohn's disease, but not for ulcerative colitis<sup>[10]</sup>.

Given the adverse effects of active IBD and associated effects on pregnancy outcomes, careful monitoring

during this period is an important but challenging aspect of care. Ideally, disease activity should be objectively assessed prior to pregnancy as a part of conception planning. Endoscopy showing histological mucosal healing is an important predictor of clinical outcomes. This is particularly important since the correlation of clinical symptoms and histologic disease can be weak, especially in Crohn's disease. Therefore, having an objective assessment of disease activity during pregnancy is crucial as this directly affects important management decisions, such as medication changes, in order to keep the pregnant patient in remission through the prenatal course.

To this end, the purpose of our review paper is to discuss the current landscape of research on the safety, efficacy and utility of various methods of monitoring IBD activity during pregnancy (Table 1).

## LOWER ENDOSCOPY

Endoscopy is the most definitive method of monitoring and evaluating disease activity. However, endoscopic procedures have been theorized to pose a threat to the fetus through the possibility of intra-procedural maternal hypoxia and hypotension, which can cause fetal hypoxia and potential demise<sup>[11]</sup>. Additionally, sedating medications, prolonged procedure times, and maternal positioning during endoscopy can potentially have significant effects on maternal circulation. Here, we have categorized lower endoscopy into colonoscopy and flexible sigmoidoscopy due to their separate risks and benefits.

### Colonoscopy

Colonoscopy may be indicated in a pregnancy state, to evaluate the extent of ulcerative colitis that may determine the need for additional immunosuppressive agents or in small bowel Crohn's disease. A systematic review of lower gastrointestinal endoscopies performed in all three trimesters of pregnancy evaluated any adverse pregnancy outcomes that were noted to be in a temporal or etiological relation with the procedure<sup>[12]</sup>. This review comprised of 100 endoscopies, with a total of six reported adverse events that were related to the procedure. The authors concluded that colonoscopy is not only a low-risk procedure during pregnancy, but also that there were no significant changes in adverse events between the three trimesters. Furthermore, a prospective study done by de Lima *et al*<sup>[13]</sup> compared 42 pregnant IBD patients who underwent lower endoscopy (13 colonoscopies and 33 sigmoidoscopies) with case-matched pregnant IBD patients who did not undergo endoscopy. The adverse events were two spontaneous abortions, which were likely related to the endoscopic procedure; however, this was not a statistically significant difference when compared to the control group. There remains a gap of literature on safety of endoscopy in pregnant patients; but early studies appear



**Table 1 Overview of various disease monitoring modalities and their pros/cons in pregnant inflammatory bowel disease patients**

Monitoring modality	Pros	Cons
Lower endoscopy		
Colonoscopy	Gold standard of disease monitoring Early studies show no difference in adverse events between pregnant IBD patients who underwent colonoscopy and who did not undergo colonoscopy	Limited studies Provider/patient hesitancy due to procedural and anesthetic concerns
Flexible sigmoidoscopy	Can be performed without sedation No case reports of any procedure-related complications	Limited studies
Radiologic studies		
Ultrasound	Safest form of radiologic imaging Contrast-enhanced ultrasound shown to have good results in IBD	Sensitivity in pregnancy unknown
Magnetic resonance imaging	No use of damaging ionizing radiation  Can detect luminal and extraluminal abnormalities Long-term safety after exposure to MRI trimester of pregnancy showed no increased risk of harm to the fetus or in early childhood	Currently no well-controlled studies of the teratogenic effects of gadolinium contrast in pregnant women have been performed and the fetal risk is unknown
Biomarkers		
Albumin	Low albumin shown to be predictor of poor outcomes in IBD	Limited utility in pregnancy due to pregnancy-induced hemodilution resulting in lower albumin values
ESR	Generally a good marker of inflammation and reflects disease activity	Limited utility in pregnancy due to physiologic increase in ESR (2-3 x upper limit of normal)
CRP	Levels are only slightly raised in normal pregnancy and are still under the normal limits CRP higher in clinically active pregnant IBD patients at preconception and first trimester compared to clinically inactive pregnant IBD patients	May not accurately reflect disease activity in second and third trimester Limited studies in pregnant IBD population
FCP	Measure of GI mucosal inflammatory activity detected prior to signs of systemic inflammation Multiple studies showing correlation between FCP levels and non-invasive disease activity scores in CD and UC	Conflicting evidence for utility of FCP in IBD during pregnancy Limited studies with actual endoscopic data to evaluate clinical activity

IBD: Inflammatory bowel disease; CD: Crohn's disease; MRI: Magnetic resonance imaging; UC: Ulcerative colitis; CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate; FCP: Fecal calprotectin.

to suggest that endoscopy when necessary is shown to be a low-risk and safe procedure in any trimester.

### **Flexible sigmoidoscopy**

Unsedated flexible sigmoidoscopy is an alternative approach to evaluate the rectum and left colon, thereby avoiding the risks of anesthesia. It plays an important role in determining the severity of mucosal disease in patients with refractory colitis and to evaluate concomitant infections. Based on reviews of retrospective studies and case series, it seems that performing an unsedated flexible sigmoidoscopy in a pregnant woman is quite safe<sup>[14]</sup>. None of the studies or case reports indicated any procedure-related complications to either the mother or fetus. In addition, the timing of the procedure did not seem to matter given that sigmoidoscopies were safely performed during all three trimesters.

### **Safety of anesthetics and colon cleansing agents**

According to a joint statement from the American Society of Anesthesiologists and the American College of Obstetrics and Gynecology, none of the currently used anesthetic agents, when used in standard concentrations at any gestational age, have been shown to have any teratogenic effect in humans. There is currently

an insufficient amount of data on the safety of colon cleansing agents in the pregnant population. Polyethylene glycol electrolyte isotonic cathartic solutions have not been studied in pregnancy, and are classified as pregnancy category C. Sodium phosphate preparations (category C) may cause fluid and electrolyte abnormalities and should be used with caution. Tap water enemas may be sufficient for flexible sigmoidoscopy in a pregnant patient.

## **RADIOLOGIC STUDIES**

In general, imaging with non-ionizing radiation is preferred over modalities with ionizing radiation in pregnancy. In utero radiation exposure to a developing fetus includes intrauterine growth restriction, microsomia, mental retardation, organ malformation, and childhood cancers. These risks are dependent on the gestational age at the time of exposure and the absorbed radiation dose levels. Traditionally, abdominal plain films and computed tomography (CT) scans are avoided due to their high levels of ionizing radiation. However, consensus statements from the American College of Obstetricians and Gynecologists, American College of Radiology, and International Commission on Radiological Protection have

all concluded that radiation doses less than 50 mGy are shown to have negligible risk to the fetus. Therefore, most properly done diagnostic procedures do not present a measurably increased risk to the fetus and should be performed in cases of diagnostic necessity<sup>[15]</sup>.

### **Ultrasound**

Ultrasound is the safest form of radiologic imaging in pregnancy; it can be used to assess abscess formation along with the location and length of the affected segment of bowel. More recently, contrast enhanced ultrasound has been studied in inflammatory bowel disease with good results. It is an emerging technique to evaluate disease activity, the differentiation between small bowel stricture due to inflammation or mural fibrosis, and for the assessment of response to specific therapies<sup>[16]</sup>. Its sensitivity in pregnancy needs to be investigated.

### **Magnetic resonance imaging**

The principal advantage of MRI over ultrasonography and CT scan is the ability to image deep soft tissue structures in a manner that is less operator dependent and does not use ionizing radiation. As per the guidelines from the American College of Obstetrics and Gynecologists, there are no precautions or contraindications for MRI specific to the pregnant woman<sup>[17]</sup>. It is being used now in routine obstetric care. MRI has been used to diagnose terminal ileal CD during pregnancy<sup>[18]</sup>.

Use of gadolinium based contrast agents (GBCA) in MRI during pregnancy: To date, there have been no known adverse effects to human fetuses reported when clinically recommended dosages of GBCA have been given to pregnant women. A single prospective cohort study of 26 women exposed to gadolinium chelates during the first trimester of pregnancy showed no evidence of teratogenesis or mutagenesis in their progeny<sup>[19]</sup>.

There are no known cases of nephrogenic systemic fibrosis associated to the use of GBCAs in pregnant patients. However, gadolinium chelates may accumulate in the amniotic fluid which has the potential for the dissociation of the toxic free gadolinium ion. This is swallowed by the fetus and enters the fetal circulation possibly conferring risk to the fetus. Currently no well-controlled studies of the teratogenic effects of these media in pregnant women have been performed and the fetal risk is unknown.

Both the American College of Radiology and the American College of Obstetrics and Gynecology conclude that gadolinium contrast with MRI should be used with caution; it may be used as a contrast agent in a pregnant woman only if it significantly improves diagnostic performance and is expected to improve fetal or maternal outcome, outweighing the possible but unknown risk of fetal exposure to free gadolinium ions. Lowest possible dose should be used to achieve diagnostic results. Contrast enhanced MRI may be useful to evaluate for abscess or fistulas.

### **Abdominal X ray**

Traditionally X-rays are avoided in pregnancy due to fear of fetal risks from ionizing radiation. The maximal risk attributed to a 1-rad exposure, approximately 0.003%, is thousands of times smaller than the spontaneous risks of malformations, abortion, or genetic disease<sup>[20]</sup>. One abdominal X ray results in fetal exposure to radiation to 0.1 rad<sup>[21]</sup>. Therefore, in diagnosis of toxic megacolon, the risks to the fetus of an abdominal X-ray (1 in 30000) compared to the condition being poorly managed (60% fetal mortality rate) indicate that the patient should be imaged as would a non-pregnant patient. In conclusion, in cases of emergent situation or when other modalities are not available, an abdominal X ray would prove to be an important test.

---

## **BIOMARKERS**

---

Serum and fecal biomarkers play an important role in non-invasive monitoring of the disease activity in IBD patients.

### **Albumin**

Albumin is routinely used to assess overall disease activity state and its impact on the body. Patients with active disease may lose protein/albumin from the inflamed mucosa. Low albumin has shown to be a predictor of poor outcomes in inflammatory bowel disease. However, there are normal physiological changes in some laboratory parameters in pregnancy that should not be attributed to disease activity. Pregnancy causes hemodilution, resulting in fall in albumin by about 1 mg/dL by the end of 1<sup>st</sup> trimester. Hence, albumin of 2 mg/L during the third trimester in a patient with baseline albumin of 3 mg/L may not reflect worsening disease activity.

### **Erythrocyte sedimentation rate**

Erythrocyte sedimentation rate (ESR) is a marker of inflammation and reflects disease activity. Pregnancy causes a physiological increase in ESR from increase fibrinogen levels. The increase is about 2 to 3 times upper limit of normal by the first trimester. Hence an elevated ESR of 40 mm/h may reflect normal health in a third trimester pregnancy female. Thus, ESR values merit careful interpretation in evaluation of the disease activity in pregnant state.

### **C-reactive protein**

C-reactive protein (CRP) is another marker of inflammation and reflects disease activity. Its levels are usually unaltered or possibly only slightly raised in normal pregnancy compared to a non-pregnant state, however the levels are still under the normal limits<sup>[22]</sup>. In a prospective study, Bal *et al*<sup>[23]</sup> evaluated the association of elevated CRP with clinical disease activity during pregnancy among women with IBD. The median CRP was numerically higher in women with clinically active disease

compared to those with clinically inactive disease at preconception (6.95 vs 2.80 mg/L,  $P = 0.559$ ) and first trimester (24.75 vs 6.00 mg/L,  $P = 1.000$ ), respectively. However, surprisingly the median CRP was lower in women with clinically active disease compared to those with clinically inactive disease at second trimester (8.85 vs 12.40 mg/L,  $P = 0.5923$ ), and third trimester (5.45 vs 11.90 mg/L,  $P = 0.592$ ), respectively. Their study shows that CRP remains a potential tool for assessing IBD disease activity in the early trimesters of pregnancy; however, it may not accurately reflect the disease activity in later trimesters. It is possible that in their study, concomitant minor infections in later trimesters might have increased CRP in healthy pregnancy patients with silent IBD. More research is needed to clearly identify the response of CRP in pregnancy state with IBD. At present, most physicians consider CRP as a useful tool in monitoring disease activity during pregnancy.

### **Fecal calprotectin**

Among various different biological markers, fecal calprotectin (FCP) has emerged as the most superior marker to diagnose or monitor inflammatory bowel disease. Calprotectin is a heterodimer of two S100 proteins (S100A8 and S100A9), which are a family of calcium-binding proteins that are linked to innate immune functions through their expression in macrophages, monocytes, phagocytes, and granulocytes<sup>[24]</sup>. These proteins are released during periods of inflammation from gastrointestinal epithelial cells. Therefore, fecal calprotectin can be used as a measure of gastrointestinal mucosal inflammatory activity that is detected prior to signs of systemic inflammation, such as elevations in CRP or ESR<sup>[25]</sup>.

Elevation of fecal calprotectin concentrations is shown to predict disease relapse in the next 12 mo in IBD, although this association is stronger in UC than in CD<sup>[26,27]</sup>. A recent prospective study showed that fecal calprotectin level below 50 ug/g is predictive of histologic remission in quiescent UC<sup>[28]</sup>. While there are a multitude of studies that have successfully shown the use of fecal calprotectin in monitoring IBD, its utility in pregnancy has not been fully elucidated yet.

### **Does pregnancy affect FCP levels?**

To evaluate the utility of FCP as marker for active IBD disease during pregnancy, the effects of normal pregnancy on FCP need to be established. A recent prospective study involving 135 patients compared the concentrations of FCP in healthy non-pregnant and pregnant women and in patients with inflammatory bowel disease<sup>[29]</sup>. Stool samples were taken during each trimester, and there were no significant difference ( $P < 0.092$ ) between FCP concentrations during each trimester. The mean FCP concentration between pregnant and non-pregnant health women showed no statistically significant difference, suggesting that pregnancy itself does not cause an elevation in FCP markers. While the FCP concentrations between patients

with IBD and healthy controls were statistically different, no pregnant patients with IBD were included in this study; therefore, it is difficult to draw a conclusion on the combined influence of IBD and pregnancy on FCP levels.

### **Evidence for utility of FCP in IBD during pregnancy**

To date, there have been a few recent studies assessing the utility of FCP in IBD during pregnancy. Initial results have been conflicting, with some showing good correlation between FCP levels and non-invasive disease activity score in CD and UC, while others showed that it is a poor predictor of IBD relapse during pregnancy. Huang *et al* enrolled seventeen pregnant IBD patients in a prospective study, in which fecal calprotectin was monitored at pre-conception and at each trimester along with modified Harvey Bradshaw Index (mHBI) for Crohn's disease and partial Mayo score for ulcerative colitis patients. The median FCP values for women with clinically active disease (as measured by mHBI  $\geq 5$  and partial Mayo score  $\geq 2$ ) were numerically higher than women with clinically inactive disease, but did not reach statistical significance at all-time points<sup>[30]</sup>.

A prospective study by Shitrit *et al*<sup>[31]</sup> enrolled 33 pregnant women with IBD, and compared fecal calprotectin levels with partial Mayo and Harvey Bradshaw index scores, along with serum ESR, CRP, and albumin levels. No correlation was noted between FCP and clinical scores, albumin, and inflammatory serum markers, although a subsequent study by the same group using 80 samples from 57 pregnant patients did show a positive correlation between stool calprotectin and Crohn's disease activity index and partial Mayo scores ( $r = 0.60$  and  $r = 0.77$ , respectively)<sup>[32]</sup>. FCP showed a high sensitivity and specificity in the occurrence of disease activity (as determined by the clinician) at 81.8% and 80.7% in a prospective study by Kanis *et al*<sup>[33]</sup>; however, there was no correlation between an elevated FCP and subsequent disease relapse. Ultimately, there is no clear consensus at this time with these small prospective studies showing conflicting results. FCP should be used in conjunction with clinical judgment, and appears to be an unreliable predictor of IBD relapse in the setting of pregnancy.

## **DISCUSSION**

Monitoring IBD during pregnancy continues to be an important challenge for clinicians. Recent data seems to suggest that endoscopy, both colonoscopy and flexible sigmoidoscopy, is a relatively safe procedure during all trimesters of pregnancy. MRI and ultrasound remain the safest methods of imaging during pregnancy. Serum biomarkers such as CRP and fecal calprotectin are helpful non-invasive markers, but have shown conflicting results for correlation with disease activity in some initial studies. Further investigation into these non-invasive biomarkers is necessary. Careful monitoring during this period remains a crucial component for important management



decisions to keep the patient in remission throughout the prenatal course.

## REFERENCES

- 1 **Mountfield R**, Bampton P, Prosser R, Muller K, Andrews JM. Fear and fertility in inflammatory bowel disease: a mismatch of perception and reality affects family planning decisions. *Inflamm Bowel Dis* 2009; **15**: 720-725 [PMID: 19067431 DOI: 10.1002/ibd.20839]
- 2 **Selinger CP**, Eaden J, Selby W, Jones DB, Katelaris P, Chapman G, McDonald C, McLaughlin J, Leong RW, Lal S. Patients' knowledge of pregnancy-related issues in inflammatory bowel disease and validation of a novel assessment tool ('CCPKnow'). *Aliment Pharmacol Ther* 2012; **36**: 57-63 [PMID: 22568682 DOI: 10.1111/j.1365-2036.2012.05130.x]
- 3 **Selinger CP**, Eaden J, Selby W, Jones DB, Katelaris P, Chapman G, McDonald C, McLaughlin J, Leong RW, Lal S. Inflammatory bowel disease and pregnancy: lack of knowledge is associated with negative views. *J Crohns Colitis* 2013; **7**: e206-e213 [PMID: 23040449 DOI: 10.1016/j.crohns.2012.09.010]
- 4 **Dubinsky M**, Abraham B, Mahadevan U. Management of the pregnant IBD patient. *Inflamm Bowel Dis* 2008; **14**: 1736-1750 [PMID: 18626967 DOI: 10.1002/ibd.20532]
- 5 **Rajaratnam SG**, Eglinton TW, Hider P, Fearhead NS. Impact of ileal pouch-anal anastomosis on female fertility: meta-analysis and systematic review. *Int J Colorectal Dis* 2011; **26**: 1365-1374 [PMID: 21766164 DOI: 10.1007/s00384-011-1274-9]
- 6 **Abdul Sultan A**, West J, Ban L, Humes D, Tata LJ, Fleming KM, Nelson-Piercy C, Card T. Adverse Pregnancy Outcomes Among Women with Inflammatory Bowel Disease: A Population-Based Study from England. *Inflamm Bowel Dis* 2016; **22**: 1621-1630 [PMID: 27306070 DOI: 10.1097/MIB.0000000000000802]
- 7 **Padhan RK**, Kedia S, Garg SK, Bopanna S, Mouli VP, Dhingra R, Makharia G, Ahuja V. Long-Term Disease Course and Pregnancy Outcomes in Women with Inflammatory Bowel Disease: An Indian Cohort Study. *Dig Dis Sci* 2017; **62**: 2054-2062 [PMID: 27785711]
- 8 **Kammerlander H**, Nielsen J, Kjeldsen J, Knudsen T, Friedman S, Nørgård B. The Effect of Disease Activity on Birth Outcomes in a Nationwide Cohort of Women with Moderate to Severe Inflammatory Bowel Disease. *Inflamm Bowel Dis* 2017; **23**: 1011-1018 [PMID: 28346274 DOI: 10.1097/MIB.0000000000001102]
- 9 **Bengtson MB**, Aamodt G, Mahadevan U, Vatn MH. Inadequate Gestational Weight Gain, the Hidden Link Between Maternal IBD and Adverse Pregnancy Outcomes: Results from the Norwegian Mother and Child Cohort Study. *Inflamm Bowel Dis* 2017; **23**: 1225-1233 [PMID: 28452861 DOI: 10.1097/MIB.0000000000001123]
- 10 **Bengtson MB**, Martin CF, Aamodt G, Vatn MH, Mahadevan U. Inadequate Gestational Weight Gain Predicts Adverse Pregnancy Outcomes in Mothers with Inflammatory Bowel Disease: Results from a Prospective US Pregnancy Cohort. *Dig Dis Sci* 2017; **62**: 2063-2069 [PMID: 28332106 DOI: 10.1007/s10620-017-4547-5]
- 11 **Nguyen GC**, Seow CH, Maxwell C, Huang V, Leung Y, Jones J, Leontiadis GI, Tse F, Mahadevan U, van der Woude CJ. IBD in Pregnancy Consensus Group; Canadian Association of Gastroenterology. The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. *Gastroenterology* 2016; **150**: 734-757.e1 [PMID: 26688268 DOI: 10.1053/j.gastro.2015.12.003]
- 12 **De Lima A**, Galjart B, Wisse PH, Bramer WM, van der Woude CJ. Does lower gastrointestinal endoscopy during pregnancy pose a risk for mother and child? - a systematic review. *BMC Gastroenterol* 2015; **15**: 15 [PMID: 25849032 DOI: 10.1186/s12876-015-0244-z]
- 13 **de Lima A**, Zelinkova Z, van der Woude CJ. A prospective study of the safety of lower gastrointestinal endoscopy during pregnancy in patients with inflammatory bowel disease. *J Crohns Colitis* 2015; **9**: 519-524 [PMID: 25939352 DOI: 10.1093/ecco-jcc/jjv079]
- 14 **Siddiqui U**, Denise Proctor D. Flexible sigmoidoscopy and colonoscopy during pregnancy. *Gastrointest Endosc Clin N Am* 2006; **16**: 59-69 [PMID: 16546023 DOI: 10.1016/j.giec.2006.01.009]
- 15 **McCollough CH**, Schueler BA, Atwell TD, Braun NN, Regner DM, Brown DL, LeRoy AJ. Radiation exposure and pregnancy: when should we be concerned? *Radiographics* 2007; **27**: 909-917; discussion 917-918 [PMID: 17620458 DOI: 10.1148/rg.274065149]
- 16 **Quaia E**. Contrast-enhanced ultrasound of the small bowel in Crohn's disease. *Abdom Imaging* 2013; **38**: 1005-1013 [PMID: 23728306 DOI: 10.1007/s00261-013-0014-8]
- 17 **American College of Obstetricians and Gynecologists' Committee on Obstetric Practice**. Committee Opinion No. 656: Guidelines for Diagnostic Imaging During Pregnancy and Lactation. *Obstet Gynecol* 2016; **127**: e75-e80 [PMID: 26942391 DOI: 10.1097/00006250-201602000-00055]
- 18 **Shoenut JP**, Semelka RC, Silverman R, Yaffe CS, Micflikier AB. MRI in the diagnosis of Crohn's disease in two pregnant women. *J Clin Gastroenterol* 1993; **17**: 244-247 [PMID: 8228087]
- 19 **De Santis M**, Straface G, Cavaliere AF, Carducci B, Caruso A. Gadolinium periconceptional exposure: pregnancy and neonatal outcome. *Acta Obstet Gynecol Scand* 2007; **86**: 99-101 [PMID: 17230297 DOI: 10.1080/00016340600804639]
- 20 **Brent RL**. The effect of embryonic and fetal exposure to x-ray, microwaves, and ultrasound: counseling the pregnant and nonpregnant patient about these risks. *Semin Oncol* 1989; **16**: 347-368 [PMID: 2678486]
- 21 **Hufton AP**. Radiation dose to the fetus in obstetric radiography. *Br J Radiol* 1979; **52**: 735-740 [PMID: 476388 DOI: 10.1259/0007-1285-52-52-621-735]
- 22 **Watts DH**, Krohn MA, Wener MH, Eschenbach DA. C-reactive protein in normal pregnancy. *Obstet Gynecol* 1991; **77**: 176-180 [PMID: 1988876 DOI: 10.1097/00006250-199102000-00002]
- 23 **Bal J**, Foshaug R, Ambrosio L, Kroeker KI, Dieleman L, Halloran B, Fedorak RN, Huang VW. P247 C-reactive protein is elevated with clinical disease activity during pregnancy in women with Inflammatory Bowel Disease. ECCO Abstracts 2015. Available from: URL: <https://www.ecco-ibd.eu/publications/congress-abstract-s/abstracts-2015/item/p247-c-reactive-protein-is-elevated-with-clinical-disease-activity-during-pregnancy-in-women-with-in-inflammatory-bowel-disease.html>
- 24 **Siddiqui I**, Majid H, Abid S. Update on clinical and research application of fecal biomarkers for gastrointestinal diseases. *World J Gastrointest Pharmacol Ther* 2017; **8**: 39-46 [PMID: 28217373 DOI: 10.4292/wjgpt.v8.i1.39]
- 25 **Gisbert JP**, McNicholl AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. *Dig Liver Dis* 2009; **41**: 56-66 [PMID: 18602356 DOI: 10.1016/j.dld.2008.05.008]
- 26 **Tibble JA**, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. *Gastroenterology* 2000; **119**: 15-22 [PMID: 10889150 DOI: 10.1053/gast.2000.8523]
- 27 **Costa F**, Mumolo MG, Ceccarelli L, Bellini M, Romano MR, Sterpi C, Ricchiuti A, Marchi S, Bottai M. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. *Gut* 2005; **54**: 364-368 [PMID: 15710984 DOI: 10.1136/gut.2004.043406]
- 28 **Shi HY**, Chan FK, Higashimori A, Chan A, Ching J, Wu JC, Sung J, Ng SC. Fecal calprotectin below 50ug/g predicts histologic remission: a prospective cohort study in quiescent ulcerative colitis. AGA abstracts 2016 [DOI: 10.1016/S0016-5085(16)33342-X]
- 29 **Bálint A**, Berényi A, Farkas K, Pallagi Kunstar É, Altorjay Á, Csonka A, Krizsán M, Szűcs M, Pál A, Fábán A, Bor R, Milassin Á, Szulcsán Á, Mariann R, Szepes Z, Molnár T. Pregnancy does not affect fecal calprotectin concentration in healthy women. *Turk J Gastroenterol* 2017; **28**: 171-175 [PMID: 28336498 DOI: 10.5152/tjg.2017.16711]
- 30 **Huang V**, Bal J, Foshaug RR. Su1255 Fecal Calprotectin Is Elevated With Clinical Disease Activity During Pregnancy in Women With Inflammatory Bowel Disease. *Gastroenterology* 2015; **148** Suppl 1: S452 [DOI: 10.1016/S0016-5085(15)31526-2]
- 31 **Shitrit ABD**, Miznikov I, Adar T, Goldin E. Su1252 Limitations in

- Using Fecal Calprotectin As a Biomarker of IBD Disease Activity During Pregnancy. *Gastroenterology* 2015; **148** Suppl 1: S452
- 32 **Schweistein H**, Adar T, Shteingart S, Raveh I A, Granovsky-Grisaru S, Goldin E, Shitrit A. P135 Serum Chitinase 3-like-1 (CHI3L1) and faecal calprotectin levels for non-invasive disease activity assessment in inflammatory bowel disease patients during pregnancy. *Gastroenterology* 2016; **150** Suppl 1: S987 [DOI: 10.1016/S0016-5085(16)33340-6]
- 33 **Kanis SL**, de Lima A, Van Oorschot V, Van Der Woude CJ. Su1802 Fecal Calprotectine Is a Poor Predictor of IBD Relapse During Pregnancy. *Gastroenterology* 2016; **150** Suppl 1: S556 [DOI: 10.1016/S0016-5085(16)31901-1]

**P- Reviewer:** Ahluwalia NK, Yalniz M **S- Editor:** Qi Y  
**L- Editor:** A **E- Editor:** Li RF





Published by **Baishideng Publishing Group Inc**  
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA  
Telephone: +1-925-223-8242  
Fax: +1-925-223-8243  
E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjgnet.com>

